Cardiovascular and heart failure safety profile of vildagliptin: a meta‐analysis of 17 000 patients
The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Aims: To report the cardiovascular ( CV ) safety profile and heart failure ( HF ) risk of vildagliptin from a large pool of studies, including trials in high‐risk patients with type 2 diabetes mellitus ( T2DM ), such as those with congestive HF and/or moderate/severe renal impairment. Methods: We conducted a retrospective meta‐analysis of prospectively adjudicated CV events. Patient‐level data were pooled from 40 double‐blind, randomized controlled phase III and IV vildagliptin studies. The primary endpoint was occurrence of major adverse CV events ( MACEs ; myocardial infarction, stroke and CV death). Assessments of the individual MACE components and HF events (requiring hospitalization or new onset) were secondary endpoints. The risk ratio ( RR ) of vildagliptin (50 mg once‐ and twice‐daily combined) versus comparators (placebo and all non‐vildagliptin treatments) was calculated using the M antel– H aenszel ( M–H ) method. Results: Of the 17 446 patients, 9599 received vildagliptin (9251.4 subject‐years of exposure) and 7847 received comparators (7317.0 subject‐years of exposure). The mean age of the patients was 57 years, body mass index 30.5 kg/m 2 (nearly 50% obese), glycated haemoglobin concentration 8.1% and T2DM duration 5.5 years. A MACE occurred in 83 (0.86%) vildagliptin‐treated patients and 85 (1.20%) comparator‐treated patients, with an M‐H RR of 0.82 [95% confidence interval ( CI ) 0.61–1.11]. Similar RRs were observed for the individual events. Confirmed HF events were reported in 41 (0.43%) vildagliptin‐treated patients and 32 (0.45%) comparator‐treated patients, with an M–H RR 1.08 (95% CI 0.68–1.70). Conclusions: This large meta‐analysis indicates that vildagliptin is not associated with an increased risk of adjudicated MACEs relative to comparators. Moreover, this analysis did not find a significant increased risk of HF in vildagliptin‐treated patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
The Emerging Risk Factors Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)60484-9 · Cited by 5,125
Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes
Nissen, S. E., & Wolski, K. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072761 · Cited by 4,675
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus
Scirica, B. M., Bhatt, D. L., Braunwald, E., Steg, P. G., Davidson, J., Hirshberg, B., Ohman, P., Frederich, R., Wiviott, S. D., Hoffman, E. B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1307684 · Cited by 3,470
Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes
Green, J. B., Bethel, M. A., Armstrong, P. W., Buse, J. B., Engel, S. S., Garg, J., Josse, R., Kaufman, K. D., Koglin, J., Korn, S., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501352 · Cited by 2,577 · cited 5×
“It is important to note that the recently completed TECOS trial reported an HR of 1.00 for HF hospitalization [13].”
BackgroundResultInfluentialAlogliptin after acute coronary syndrome in patients with type 2 diabetes
White, W. B., Cannon, C. P., Heller, S. R., Nissen, S. E., Bergenstal, R. M., Bakris, G. L., Perez, A. T., Fleck, P. R., Mehta, C. R., Kupfer, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305889 · Cited by 2,502 · cited 9×
“Many studies included in the meta-analysis were of short duration, but the average length of treatment of ∼1 year is little different from the median duration of treatment in the SAVOR-TIMI-53 (2.1 years) [11] and EXAMINE trials (18 months) [12].”
BackgroundResultInfluentialZannad, F., Cannon, C. P., Cushman, W. C., Bakris, G. L., Menon, V., Perez, A. T., Fleck, P. R., Mehta, C. R., Kupfer, S., Wilson, C., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)62225-x · Cited by 757
Rosenstock, J., Kim, S. W., Baron, M. A., Camisasca, R. ‐., Cressier, F., Couturier, A., & Dejager, S. (2007) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2006.00698.x · Cited by 255
Cardiovascular outcome trials of glucose-lowering drugs or strategies in type 2 diabetes
Holman, R. R., Sourij, H., & Califf, R. M. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60794-7 · Cited by 227
Rosenstock, J., Foley, J. E., Rendell, M., Landin-Olsson, M., Holst, J. J., Deacon, C. F., Rochotte, E., & Baron, M. A. (2008) · Diabetes Care · doi:10.2337/dc07-1616 · Cited by 153
Foley, J. E., Bunck, M. C., Möller-Goede, D. L., Poelma, M., Nijpels, G., Eekhoff, E. M., Schweizer, A., Heine, R. J., & Diamant, M. (2011) · Diabetologia · doi:10.1007/s00125-011-2167-8 · Cited by 83
Self-citation
Cited by
Nauck, M. A., Meier, J. J., Cavender, M. A., Abd El Aziz, M., & Drucker, D. J. (2017) · Circulation · doi:10.1161/circulationaha.117.028136 · Cited by 582
Tirzepatide cardiovascular event risk assessment: A pre-specified meta-analysis
Sattar, N., McGuire, D. K., Pavo, I., Weerakkody, G. J., Nishiyama, H., Wiese, R. J., & Zoungas, S. (2022) · Nature Medicine · doi:10.1038/s41591-022-01707-4 · Cited by 346
Cardiovascular Effects of New Oral Glucose-Lowering Agents: DPP-4 and SGLT-2 Inhibitors
Scheen, A. J. (2018) · Circulation Research · doi:10.1161/circresaha.117.311588 · Cited by 286
Jarolim, P., White, W. B., Cannon, C. P., Gao, Q., & Morrow, D. A. (2018) · Diabetes Care · doi:10.2337/dc18-0109 · Cited by 56
Scheen, A. J. (2017) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2017.03.009 · Cited by 18
Metadata
- Authors
- McInnes, G., Evans, M., Del Prato, S., Stumvoll, M., Schweizer, A., Lukashevich, V., Shao, Q., & Kothny, W.
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2015-09-10
- Volume
- 17
- Issue
- 11
- Pages
- 1085-1092
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W1846464686
- Cited by
- 107
- References
- 11
- FWCI
- 12.66
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.